Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sublingual Versus Intrauterine MISOPROSTOL in Addition to Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Randomized Placebo Controlled Trial

NCT04560218 is registered in ClinicalTrials.gov with Department of Medical Services Ministry of Public Health of Thailand as lead sponsor.

NCT NCT04560218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04560218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sublingual Versus Intrauterine MISOPROSTOL in Addition to Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Randomized Placebo Controlled Trial
Lead sponsor
Department of Medical Services Ministry of Public Health of Thailand
Phase
Phase 3
Overall status
Completed
Start date
October 30, 2020
Completion date
September 10, 2021
Enrollment
135 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

to compare efficacy intrauterine vs sublingual misoprostol in addition to oxytocin in reducing blood loss of post-cesarean section in high risk women